After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine
Biotechnology firm Paragon Labs has brought in the former senior leadership team of Apogee Therapeutics following AbbVie's acquisition of Apogee. The new executives include CEO Michael Henderson, Head of R&D Carl Dambkowski, Chief Business and Financial Officer Dan Mulreany, Chief Legal Officer Matt Batters, and Chief People Officer Emily Cox. The team will oversee the advancement of Paragon-discovered drug candidates into clinical development and build new biotechnology companies around promising therapeutic assets, beginning with Velaris Therapeutics.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Paragon Labs appointed former Apogee CEO Michael Henderson as its new chief executive.
- ✓ Additional former Apogee executives joining Paragon include Carl Dambkowski as head of R&D, Dan Mulreany as chief business and financial officer, Matt Batters as chief legal officer, and Emily Cox as chief people officer.
- ✓ Alaunos Therapeutics completed its acquisition of Velaris Therapeutics.
What changed
Paragon Labs officially expanded its leadership team by integrating the former top executives of Apogee Therapeutics.
Live updates
-
Paragon Labs Hires Former Apogee Executives to Scale R&D
Biotechnology firm Paragon Labs has brought in the former senior leadership team of Apogee Therapeutics following AbbVie's acquisition of Apogee. The new executives include CEO Michael Henderson, Head of R&D Carl Dambkowski, Chief Business and Financial Officer Dan Mulreany, Chief Legal Officer Matt Batters, and Chief People Officer Emily Cox. The team will oversee the advancement of Paragon-discovered drug candidates into clinical development and build new biotechnology companies around promising therapeutic assets, beginning with Velaris Therapeutics.
Why it matters
The executive transition follows a reported $10.9 billion acquisition of Apogee Therapeutics by AbbVie. Paragon operates as a biotechnology creator focused on discovering and developing differentiated biologics. The newly expanded leadership aims to accelerate the translation of research assets into clinical-stage medicines.
What is confirmed
- Paragon Labs appointed former Apogee CEO Michael Henderson as its new chief executive.
- Additional former Apogee executives joining Paragon include Carl Dambkowski as head of R&D, Dan Mulreany as chief business and financial officer, Matt Batters as chief legal officer, and Emily Cox as chief people officer.
- Alaunos Therapeutics completed its acquisition of Velaris Therapeutics.
What to watch next
- Clinical development updates for Paragon-discovered assets under the new leadership team.
- Further company creation milestones starting with Velaris Therapeutics.
confidence 100%Sources used for this update (12)
- Endpoints News — After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine
- Fierce Biotech — Biotech builder Paragon imports Apogee's top brass after AbbVie buyout
- BioPharma Dive — Another Paragon spinout goes public through reverse merger
- PR Newswire — Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
- www.marketscreener.com — Alaunos Therapeutics, Inc. announced that it expects to receive $349.953008 million in funding
- finviz.com — Paragon Labs Expands Leadership Team with Former Apogee ...
- finance.yahoo.com — Paragon Labs Expands Leadership Team with Former Apogee ...
- finance.biggo.com — Paragon Labs Names Former Apogee CEO to Lead Company After ...
- stocktwitspr.com — Paragon Recruits Apogee’s Former Leaders After $10.9 Billion ...
- www.rttnews.com — Paragon Labs Adds Former Apogee Leaders As Alaunos Completes ...
- third-news.com — Paragon Labs Welcomes Former Apogee Leaders and Acquires ...
- www.finanznachrichten.de — Paragon Labs Adds Former Apogee Leaders As Alaunos Completes ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community